Altimmune Inc. Announces 2026 Annual Stockholders Meeting

Reuters03-06
Altimmune Inc. Announces 2026 Annual Stockholders Meeting

Altimmune, Inc. will hold its 2026 annual meeting virtually on April 16, 2026. Stockholders will vote on the election of nine directors and the ratification of Ernst & Young LLP as independent registered public accounting firm for 2026. The meeting will also include an advisory vote on executive compensation and a proposal to amend the company’s certificate of incorporation to increase authorized common shares from 200 million to 400 million. In addition, stockholders will vote on an amendment to the 2019 Employee Stock Purchase Plan to increase the share reserve from 403,500 to 1,108,827, and on authorization to adjourn the meeting if needed to solicit additional proxies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001326190-26-000020), on March 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment